Rubius Therapeutics (Rubius Therapeutics) GF Score : 0/100 (As of May. 07, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rubius Therapeutics GF Score?

Rubius Therapeutics has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Rubius Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Rubius Therapeutics (OTCPK:RUBY) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Rubius Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Rubius Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Rubius Therapeutics (Rubius Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (OTCPK:RUBY) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

124 Washington Street, Suite 101, Foxborough, MA, USA, 02035

Website

https://www.rubiustx.com

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Executives

Dannielle Appelhans	officer: CEO and President	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Pablo J Cagnoni	director, officer: Chief Executive Officer	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laurence A. Turka	officer: Chief Scientific Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139
Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Maiken Keson-brookes	officer: CLO & Corp. Secretary	35 OAK HILL ROAD, FAYVILLE MA 01745
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Jose Carmona	officer: Chief Financial Officer	C/O INNOCOLL HOLDINGS PLC, 3803 WEST CHESTER PIKE, NEWTOWN SQUARE PA 19073
Christina M. Coughlin	officer: Chief Medical Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139